alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › repurposing

repurposing

234 studies tagged repurposing, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
  2. Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
  3. DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18

Studies

234 studies carry this tag.

Date range

1977 to 2026

Top journals

  • Research Square 9
  • Journal of medicinal chemistry 7
  • International journal of molecular sciences 6
  • Journal of Alzheimer's disease : JAD 6
  • Nature reviews. Drug discovery 6

154 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Galantamine for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Expert opinion on drug metabolism & toxicology 2010-03 Treatments

    OF THE FIELD: Alzheimer's disease (AD) is the most frequent, age-related neurodegenerative disorder and is characterized by progressive deterioration of cognition and global functioning.

  2. Acetylcholinesterase: from 3D structure to function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Chemico-biological interactions 2010-02-04 Disease mechanisms

    By rapid hydrolysis of the neurotransmitter, acetylcholine, acetylcholinesterase terminates neurotransmission at cholinergic synapses.

  3. Caffeine and adenosine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2010-01-01 Risk factors

    Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas.

  4. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Journal of Alzheimer's disease : JAD 2010-01-01 Clinical trials

    PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD).

  5. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Drug discovery 2009-09-01 Risk factors

    Nicotinic receptors - a family of ligand-gated ion channels that mediate the effects of the neurotransmitter acetylcholine - are among the most well understood allosteric membrane proteins from a structural and functional perspective.

  6. The pharmacology of sigma-1 receptors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacology & therapeutics 2009-07-18 Brain scans and imaging

    Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated molecular chaperone in the endoplasmic reticulum of cells.

  7. Cholinesterase inhibitors and beyond

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Current Alzheimer research 2009-04 Treatments

    Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD) in the nineteen nineties with great expectations.

  8. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2009-03-01 Treatments

    N-methyl-D-aspartate receptors (NMDARs) mediate interneuronal communication and are broadly involved in nervous system physiology and pathology (Dingledine et al., 1999).

  9. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

    ✓ Peer-reviewed alzhub usefulness score 77 out of 100. Current Alzheimer research 2009-02 Treatments

    AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks.

  10. Akt/GSK3 signaling in the action of psychotropic drugs

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annual review of pharmacology and toxicology 2009-01-01 Drug development

    Psychotropic drugs acting on monoamine neurotransmission are major pharmacological treatments for neuropsychiatric conditions such as schizophrenia, depression, bipolar disorder, Tourette syndrome, ADHD, and Alzheimer disease.

  11. Mammalian nicotinic acetylcholine receptors: from structure to function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Physiological reviews 2009-01-01 Brain tissue and pathology

    The classical studies of nicotine by Langley at the turn of the 20th century introduced the concept of a "receptive substance," from which the idea of a "receptor" came to light.

  12. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMC neuroscience 2008-12-10 Vascular contributions

    Intranasal delivery provides a practical, non-invasive method of bypassing the blood-brain barrier (BBB) to deliver therapeutic agents to the brain and spinal cord.

  13. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Drug discovery 2008-02-01 Risk factors

    Carbonic anhydrases (CAs), a group of ubiquitously expressed metalloenzymes, are involved in numerous physiological and pathological processes, including gluconeogenesis, lipogenesis, ureagenesis, tumorigenicity and the growth and virulence of various pathogens.

  14. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research 2008-01-26 Treatments

    Alzheimer's disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances.

  15. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2008-01-01 Treatments

    The therapeutic arsenal for the treatment of Alzheimer's disease (AD) remains confined to a group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to provide a relief of the very late symptoms of the dementia, i.e. the cognitive and functional decline.

  16. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2007-11-30 Treatments

    A design strategy to convert a dual-binding site AChE inhibitor into triple functional compounds with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed.

  17. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of clinical investigation 2007-11-01 Drug development

    Recent epidemiological evidence suggests that some antihypertensive medications may reduce the risk for Alzheimer disease (AD).

  18. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2007-08-10 Treatments

    The neurotransmitter glutamate activates several classes of metabotropic receptor and three major types of ionotropic receptor--alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA).

  19. Drug development for CNS disorders: strategies for balancing risk and reducing attrition

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Drug discovery 2007-07-01 Costs and economics

    Disorders of the central nervous system (CNS) are some of the most prevalent, devastating and yet poorly treated illnesses.

  20. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Psychopharmacology 2007-01-16 Cognitive tests and assessment

    These early data in healthy subjects provide encouragement to consider development of AZD3480 as a novel agent for the treatment of cognitive decline in the elderly, including age-associated memory impairment and/or dementia of the Alzheimer's type.

  21. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurobiology of aging 2006-11-16 Treatments

    The NMDA antagonist, memantine (Namenda), and the cholinesterase inhibitor, donepezil (Aricept), are currently being used widely, either individually or in combination, for treatment of Alzheimer's disease (AD).

  22. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neural transmission (Vienna, Austria : 1996) 2006-10-13 Risk factors

    Acetylcholine is widely distributed in the nervous system and has been implicated to play a critical role in cerebral cortical development, cortical activity, controlling cerebral blood flow and sleep-wake cycle as well as in modulating cognitive performances and learning and memory processes.

  23. Brain nicotinic acetylcholine receptors: native subtypes and their relevance

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Trends in pharmacological sciences 2006-07-31 Risk factors

    Neuronal nicotinic acetylcholine receptors comprise a heterogeneous class of cationic channels that is present throughout the nervous system.

  24. The chemical biology of clinically tolerated NMDA receptor antagonists

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2006-06-01 Treatments

    Phase 3 (final) clinical trials have shown that memantine is effective in treating moderate-to-severe Alzheimer's disease while being well tolerated.

  25. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Drug discovery 2006-02-01 Treatments

    Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects.

  26. Memantine: a review of its use in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Drugs 2006-01-01 Treatments

    Memantine (Ebixa, Axura, Namenda, Akatinol) is a moderate-affinity, uncompetitive, voltage-dependent, NMDA-receptor antagonist with fast on/off kinetics that inhibits excessive calcium influx induced by chronic overstimulation of the NMDA receptor.

  27. Mechanism of action of memantine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current opinion in pharmacology 2005-12-20 Treatments

    Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease.

  28. The interplay of neurotransmitters in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS spectrums 2005-11-01 Treatments

    Evidence exists for both cholinergic and glutamatergic involvement in the etiology of Alzheimer's disease.

  29. Serine hydrolase targets of organophosphorus toxicants

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Chemico-biological interactions 2005-10-21 Risk factors

    Acetylcholinesterase (AChE) is one of several hundred serine hydrolases in people potentially exposed to about 80 organophosphorus (OP) compounds important as insecticides or chemical warfare agents.

  30. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Annals of neurology 2005-05-01 Drug development

    Overproduction of interleukin-1 within the brain is associated with Alzheimer's disease and other neurological conditions.

  31. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current Alzheimer research 2005-04-01 Treatments

    Recent phase 3 clinical trials have shown that memantine is effective in the treatment of both mild and moderate-to-severe Alzheimer's disease and possibly vascular dementia (multi-infarct dementia).

  32. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Psychopharmacology 2005-01-15 Treatments

    All cholinesterase inhibitors reduced cognitive deficits with the following optimal daily doses: galantamine 1.25 mg kg(-1), rivastigmine 0.5 mg kg(-1) and donepezil 0.3 mg kg(-1).

  33. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuro-Signals 2005-01-01 End-of-life care

    The two major neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterised by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively.

  34. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annals of the New York Academy of Sciences 2004-12-01 Drug development

    Owing to improving preventative, diagnostic, and therapeutic measures for cardiovascular disease and a variety of cancers, the average ages of North Americans and Europeans continue to rise.

  35. Glutamate as a therapeutic target in psychiatric disorders

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular psychiatry 2004-11-01 Clinical trials

    Glutamate is the primary excitatory neurotransmitter in the mammalian brain.

  36. Acetylcholinesterase inhibitors: novel activities of old molecules

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacological research 2004-10-01 Treatments

    The therapeutic approach for improving the cognitive function in patients with Alzheimer's disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials.

  37. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurochemistry international 2004-10-01 Brain tissue and pathology

    Alzheimer's disease (AD) is the most common form of dementia, accounting for 60-70% of cases in subjects over 65 years of age.

  38. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drugs & aging 2004-01-01 Treatments

    There is also a significant correlation between acetylcholinesterase inhibition and observed cognitive improvement.

  39. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International journal of geriatric psychiatry 2003-09-01 Treatments

    There is increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD).

  40. Treatment of Alzheimer's disease: current status and new perspectives

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet. Neurology 2003-09-01 Treatments

    Alzheimer's disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing.

  41. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of pharmacology and experimental therapeutics 2003-03-20 Treatments

    Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human alpha 3 beta 4, alpha 4 beta 2, and alpha 6 beta 4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric alpha 7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype.

  42. The glutamatergic system and Alzheimer's disease: therapeutic implications

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. CNS drugs 2003-01-01 Treatments

    Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades.

  43. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS drug reviews 2003-01-01 Treatments

    Memantine has been demonstrated to be safe and effective in the symptomatic treatment of Alzheimer's disease (AD).

  44. Adenosine receptors in the nervous system: pathophysiological implications

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Progress in neurobiology 2002-12-01 Risk factors

    Adenosine is a ubiquitous homeostatic substance released from most cells, including neurones and glia.

  45. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Life sciences 2002-10-01 Treatments

    Amaryllidaceous plants produce pharmacologically active alkaloids, galanthamine being the most interesting for its use in the treatment of Alzheimer's disease as a cholinesterase inhibitor.

  46. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochemistry 2002-03-01 Treatments

    Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer's disease under the trade name of Exelon.

  47. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European neurology 2002-01-01 Treatments

    Cholinesterase inhibitors have produced the best evidence of clinical efficacy for treating patients with Alzheimer's disease (AD).

  48. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International psychogeriatrics 2002-01-01 Treatments

    Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels.

  49. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical pharmacokinetics 2002-01-01 Treatments

    A conceptual model for cholinesterase inhibitors has been proposed, linking enzyme inhibition, clinical efficacy and adverse effects.

  50. Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Japanese Journal of Pharmacology 2002-01-01 Treatments

    A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD).

From across this tag

7 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.

All topic tags with their study counts